Abstract: Phospholipase A₂ (PLA₂) has been a recent concern given the high incidence of tumors. Increasing amounts of research report that PLA₂ is an inflammatory factor that is closely associated with tumor incidence. Moreover, it displays high specificity, minimal biological variation, is rarely affected by other inflammation markers, and has a definite relation with the differentiation in tumors of the digestive tract, such as intestinal and gastric cancers. PLA₂ is also related to the invasion mechanisms, metastasis, and apoptosis of tumors. In addition, PLA₂ can be applied to the scoring and to the clinical and medicinal treatment of the Gleason tumor, which is found in prostatic cancers of the genital system. It is also closely related to the proliferation and infiltration of ovarian cancer cells. Therefore, PLA₂ can be used as a new test index for the clinical diagnosis and treatment of tumors, which may generate a new research direction with respect to the forecasting of tumor incidence and progression. The bionomics of PLA₂ facilitate the use of inflammatory factors in the detection procedures utilized by clinical laboratories, which can monitor the conditions of cancer patients in advance and effectively customize treatment regimens for such patients.